UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 ORor 15(d) of ~~The~~the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~July 2628, 2021

Gene Biotherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-33635		27-~~0075787~~007587
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification ~~No.~~Number)

11230 Sorrento Valley Road, Suite 220 San Diego, California		92121
(Address of principal executive offices)		(Zip Code)

11230 Sorrento Valley Road, Suite 220

~~Registrant’s~~San ~~telephone number~~Diego, ~~including~~California ~~area code: (858) 414-1477~~92122

~~N/A~~(Address of Principal Executive Offices) (Zip Code)

(~~Former name or former address, if changed since last report.~~858) 414-1477

~~Check~~(Registrant’s ~~the~~Telephone ~~appropriate~~Number, ~~box~~Including ~~below~~Area ~~if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:~~Code)

(Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Title of Each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	CRXM	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 7 5.0102 ~~Regulation~~Departure FDof ~~Disclosure~~Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~April~~July 2628, 2021, ~~Gene~~Murray ~~Biotherapeutics Inc~~H. ~~(the~~Hutchison, ~~“Company”)~~age ~~issued~~82, aretired ~~press~~from ~~release~~our ~~announcing~~Board ~~its~~of ~~entrance~~Directors ~~into~~after an16 ~~agreement with~~years ~~FUJIFILM~~of ~~Diosynth~~service ~~Biotechnologies~~that ~~(“FDB”)~~commenced toin ~~manufacture~~2005. ~~the Generx [Ad5FGF-4] angiogenic gene therapy product~~Mr. ~~candidate~~Hutchison’s ~~for~~decision ~~Phase~~to 3retire ~~clinical~~was ~~evaluation~~not ~~for~~a ~~the~~result ~~treatment~~ of ~~refractory~~any ~~angina.~~disagreement Awith ~~copy of~~ the ~~press release is attached hereto as Exhibit 99~~Company.1.

~~The~~We ~~information~~issued ina ~~this~~press ~~Item~~release ~~7.01,~~relating ~~including Exhibit 99.1, shall not be deemed~~ to bethe ~~“filed”~~resignation ~~for~~which ~~purposes~~is ofattached ~~Section~~as ~~18 of~~Exhibit ~~the~~99.1 ~~Exchange Act, or otherwise subject~~ to ~~the~~this liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, regardless of the general incorporation language contained in such filingreport.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press ~~release,~~Release dated ~~April~~July 2628, 2021

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GENE BIOTHERAPEUTICS INC.
Date: July 28, 2021	GENE BIOTHERAPEUTICS, INC.
Date: April 26, 2021	By:	/s/ Christopher J. Reinhard
	By:	/s/ Christopher J. Reinhard
		Christopher J. Reinhard
		Chief Executive Officer

-3-

Filing Compare · Gene Biotherapeutics, Inc.